Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid epidemic

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Ruth Jessen Hickman, MD  |  October 1, 2020

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

Filed under:Drug UpdatesOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & RheumatologyfasinumabKnee Osteoarthritis (OA)Nerve growth factor (NGF)osteoarthritis (OA)tanezumab

How to Work with Sales & Marketing Representatives in Your Practice

Steven M. Harris, Esq.  |  January 17, 2020

Sales and marketing representatives can add tremendous value to your practice: They can generate consistent business by leveraging contacts who have services that can be referred to your practice. However, the services a sales and marketing representative provides are subject to significant scrutiny under the federal Anti-Kickback Statute and state equivalents. For this reason, the…

Filed under:Legal UpdatesPractice Support Tagged with:Anti-Kickback StatuteEliminating Kickbacks in Recovery Act (EKRA)

What Pharmacists Want Rheumatologists to Know

Linda Childers  |  May 18, 2019

Involving pharmacists in the management of chronic diseases benefits patients, says Wendy Ramey, BSPharm, RPh, CSP, a clinical pharmacy specialist in rheumatology at the University of Kentucky, Lexington. She knows this personally. As someone with rheumatoid arthritis (RA), Ms. Ramey knows pharmacists can play an important role in patient education and encouraging adherence to medications….

Filed under:Patient PerspectivePractice Support Tagged with:adherenceAssociation of Rheumatology Professionals (ARP)pharmacistprior authorizationself-injectionvaccination

The Benefits of Blood Money: OxyContin & Ethics

Philip Seo, MD, MHS  |  March 18, 2019

On Feb. 9, 2019, protesters gathered at the Guggenheim Museum in New York City to lead a march down Fifth Avenue to the Metropolitan Museum of Art.1 As a general rule, news from the world of art is not a topic discussed in these pages, but if you indulge me for just a little bit…

Filed under:EthicsOpinionRheuminationsSpeak Out Rheum Tagged with:Arthur M. Sackler FoundationDr. Mortimer and Theresa Sackler Foundationopioid crisisopioid use disordersOxyContinPurdue PharmaRaymond and Beverly Sackler Foundation

Update & Changes to the OIG Work Plan

From the College  |  February 8, 2019

Early last fall, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released its OIG Work Plan for fiscal year 2018–2019, which is a two-year framework for the audits, inspections, evaluations and investigative activities planned in support of its vision, mission, and strategic goals and objectives to maintain HHS program integrity….

Filed under:From the CollegePractice Support Tagged with:evaluation and management (E/M)HHS programMedicare AdvantageMedicare paymentsOffice of Inspector General (OIG)OIG Work PlanOpioid misuse

ah_designs / shutterstock.com

The Perils of Pain Meds Revisited

Stephen G. Gelfand, MD, FACP, FACR  |  December 18, 2018

More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…

Filed under:Analgesics Tagged with:opioid crisis

Can Rheumatologists Get More Systematic about Psychosocial Care?

Larry Beresford  |  June 21, 2018

A recent position statement by the Society of Behavioral Medicine (SBM) concludes that patients with persistent pain need better access to psychosocial care in all healthcare settings.1 The SBM offers 10 health policy recommendations for improving such access, including removing system-related barriers, providing referral tools, reimbursing for evidence-based psychosocial approaches, prioritizing generalist-level and specialist pain…

Filed under:ConditionsPatient Perspective Tagged with:Association of Rheumatology Professionals (ARP)interdisciplinaryopioid crisisphysician patient relationshippsychosocial

U.S. Senate Votes to Confirm Azar as Health Secretary

Reuters Staff  |  January 24, 2018

WASHINGTON (Reuters)—The U.S. Senate on Wednesday voted to confirm former pharmaceutical industry executive and lobbyist Alex Azar as the next Health and Human Services secretary. Azar will oversee the Trump administration’s response to the opioid epidemic, its efforts to weaken the Affordable Care Act, commonly called Obamacare, and address rising prescription drug prices. The Senate…

Filed under:Uncategorized Tagged with:Alex AzarHealth and Human Services secretary

U.S. Senate Committee Advances Azar Nomination as Health Secretary

Reuters Staff  |  January 18, 2018

WASHINGTON (Reuters)—A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar’s nomination, with all but one Democrat opposing….

Filed under:Legislation & Advocacy Tagged with:nomination of Alex Azarsecretary of Health and Human ServicesU.S. Senate Finance Committee

Health Secretary Nominee Indicates Support for Medicaid Overhaul

Yasmeen Abutaleb  |  January 9, 2018

WASHINGTON (Reuters)—Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Alex AzarDepartment of Health and Human ServicesTrump administrationU.S. Department of Health and Human Services

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences